Downregulation of ER-α36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifen

Tamoxifen provided a successful treatment for ER-positive breast cancer for many years. However, HER2 overexpressing breast cancer cells respond poorly to tamoxifen therapy presumably by pass. The molecular mechanisms underlying development of tamoxifen resistance have not been well established. Rec...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Am J Cancer Res
Main Authors: Yin, Li, Pan, Xiaohua, Zhang, Xin-Tian, Guo, Yu-Ming, Wang, Zhao-Yi, Gong, Yaoqin, Wang, Molin
Formato: Artigo
Idioma:Inglês
Publicado: e-Century Publishing Corporation 2015
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4396031/
https://ncbi.nlm.nih.gov/pubmed/25973295
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares